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Abstract: Even though lung cancer patients harboring a mutation in
the epidermal growth factor receptor (EGFR) gene exhibit an initial
dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKIs),
acquired resistance is almost inevitable after a progression-free
period of approximately 10 months. A secondary point mutation that
substitutes methionine for threonine at amino acid position 790
(T790M) is a molecular mechanism that produces a drug-resistant
variant of the targeted kinase. The T790M mutation is present in
about half of the lung cancer patients with acquired resistance, and
reported to act by increasing the affinity of the receptor to adenosine
triphosphate, relative to its affinity to TKIs. Nevertheless, several
lines of evidence indicate that the T790M mutation confers growth
advantage to cancer cells, and it was shown that mice expressing
tetracycline-inducible EGFR transgenes harboring the T790M mu-
tation develop lung tumors. Thus, T790M mutation seems to play a
double role in the survival of lung cancer cells. Several second-
generation EGFR-TKIs are currently being developed to overcome
the acquired resistance caused by the T790M mutation. MET (met
proto-oncogene) amplification or activation of IGF1R are reported
as alternative mechanisms for acquired resistance to EGFR-TKIs.
Clarification of the pathways leading to acquired resistance is
essential to maximize the efficacy of EGFR-TKI therapy for patients
with lung cancer.
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Gefitinib and erlotinib are low molecular-weight epider-mal growth factor receptor (EGFR) tyrosine kinase in-
hibitors (TKI) that mimic adenosine triphosphate (ATP).
Both drugs reversibly and specifically inhibit EGFR in a
competitive fashion. About 70 to 80% of non-small cell lung
cancers harboring a somatic mutation in the tyrosine kinase
domain of the EGFR gene respond to gefitinib/erlotinib,
whereas only 10% of tumors without this mutation are re-
sponsive to these drugs;1–3 however, acquired resistance to
EGFR-TKI therapy almost always develops after a median of
approximately 10 months from the onset of treatment, even in
patients who exhibited initial dramatic responses.4
A secondary point mutation in the EGFR tyrosine
kinase domain that substitutes methionine for threonine at
amino acid position 790 (T790M) has been described as a
mechanism to explain the acquired resistance to TKIs.5,6 In
this review, we discuss the role of the T790M mutation in the
mechanism of resistance to EGFR-TKI therapy and in onco-
genesis.
EGFR and Downstream Signaling Cascades
Upon binding to its ligands, EGFR forms homo- or
heterodimers with other ERBB (erythroblastic leukemia viral
oncogene homolog avian) receptors; in addition, tyrosine
residues within the cytoplasmic domain are phosphorylated
and downstream signaling cascades are activated. These in-
clude the phosphatidylinositol-3-kinase (PI3K)-Akt pathway
(Figure 1 A) or the STAT pathway, which are mainly associated
with cell survival, and the RAS-RAF-MAPK pathway, which is
mainly associated with cell cycle progression.7,8
Somatic activating mutations in the EGFR genes were
described in 2004, mainly in patients with lung adenocarci-
noma who were female, never-smokers, and of Asian ethnic-
ity.1,2 EGFR mutation usually occurs in the first 4 exons of
the tyrosine kinase domain, and a deletion involving 5 amino
acids (codons 746–750) together with a point mutation at
codon 858 (L858R) account for 90% of all EGFR mutations.3
EGFRs harboring these mutations are constitutively activated
without ligand binding and cancer cells harboring this muta-
tion become highly dependent on the EGFR pathway, a state
often referred to as “oncogene addiction.”9,10 It is reported
that the PI3K-Akt signaling pathway is mainly activated in
EGFR-mutant cells where ERBB3 acts as a dimer partner of
EGFR, and the down-regulation of this pathway is required
for the process of gefitinib-induced apoptosis in these cells.11
In addition, mutant EGFR kinases have a higher affinity to
EGFR-TKIs (Figure 1B)12; therefore, patients with lung can-
cer harboring EGFR mutations often exhibit a dramatic re-
sponse to EGFR-TKIs.
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T790M Mutation as a cause of Acquired
Resistance to TKI Treatment
Patients with lung cancer who show an initial dramatic
response to EGFR-TKI almost always acquire resistance to
the drug after a progression-free period of approximately 10
months.4 A 2002 report described a secondary mutation in
chronic myeloid leukemia patients that substitutes isoleucine
for threonine at codon 315 of the ABL gene and causes
acquired resistance to imatinib.13 Since the T315 of ABL
corresponds to the T790 of EGFR, based on amino acid
homology, researchers investigated whether an artificial
T790M mutation conferred resistance to gefitinib and showed
that this was the case.14 Based on this report, 2 groups of
investigators confirmed that the T790M mutation is present in
patients who develop acquired resistance to EGFR-TKI treat-
ment in 2005.5,6 We and others showed that the EGFR
T790M mutation, in cis with the primary activating mutation,
occurs in approximately 50% of patients with acquired resis-
tance to EGFR-TKI treatment.15,16 Nomura et al.17 showed
that the EGFR mutations were found to favor the shorter
allele of polymorphic CA dinucleotide repeat in intron one of
the EGFR gene, and this or another genetic factor can be the
reason that the acquired T790M mutation occurs in cis, in
addition, secondary somatic activating mutation occurs in cis
with the inherited T790M mutation discussed below.
The T790 in EGFR is located at a key position in the
ATP binding cleft, often referred to as the “gatekeeper resi-
due.” Initially, it was thought that the larger methionine
residue caused steric hindrance to the binding of EGFR-
TKI5,6; however, it is difficult to explain why structurally
similar, irreversible EGFR-TKI is able to overcome the
T790M mutation, as discussed later. A recent analysis
showed that the T790M mutant retains affinity to gefitinib;
i.e., the T790M-mutant EGFR kinase binds gefitinib with a
Kd of 4.6 nM, nearly as tightly as the L858R mutant (Kd 
2.4 nM).18 In contrast, introduction of the T790M mutation
FIGURE 1. The T790M mutation plays a double role in lung cancer cell survival. A, In the inactive conformation of the epi-
dermal growth factor receptor (EGFR), the activation loop (A-loop) precludes the binding of peptide substrate. When the spe-
cific ligands bind the extracellular domain, EGFR dimerizes with other members of the ERBB family (ERBB3 in this scheme) in a
tail-to-head fashion.35 The C lobe of the kinase domain plays a role analogous to that of cyclin in activated cyclin-dependent
kinase (CDK)/cyclin complexes.35 The A-loop becomes extended to allow peptide substrate binding (active conformation),
resulting in phosphorylation of tyrosine residues in regulatory domains. Phosphorylated tyrosine residues serve as docking sites
for adaptor molecules that facilitate downstream signaling pathways, the most significant of which is the phosphatidylinositol-
3-kinase (PI3K)-Akt pathway. B, EGFR mutation (L858R in this case) also promotes formation of active conformation. Gefitinib
or erlotinib competitively inhibit binding of ATP to the EGFR kinase, resulting in inhibition of phosphorylation and down-
stream signaling. Gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.36C, When threo-
nine 790 is substituted by methionine (T790M), the ATP affinity of the oncogenic L858R mutant is increased by more
than an order of magnitude, leading to resistance to gefitinib/erlotinib.18 The T790M mutation also possesses enhanced
phosphorylating activity, especially in combination with the L858R mutation. Several lines of evidence indicate that the
T790M mutant is actually an oncogene. D, An irreversible EGFR-tyrosine kinase inhibitor (TKI) forms a covalent bond at
cysteine 797 (C) even when the T790M mutation is present, and thus is able to inhibit the T790M mutant kinase.
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increases the ATP affinity of the oncogenic L858R mutant
by more than an order of magnitude.18 The authors of this
report claim that increased ATP affinity is the primary
mechanism by which the T790M mutation confers drug
resistance (Figure 1C).18
The T790M Mutation as an Oncogenic Agent
We previously reported two examples of surgically-
treated patients who carry both the T790M and L858R
mutations, among 397 patients with EGFR mutations (0.5%)
who had never been exposed to EGFR-TKI treatment19; one
of the patients showed inherent resistance to gefitinib when
she was treated with this drug after tumor recurrence.19
Others reported a family with multiple cases of lung cancer
associated with germ line transmission of the T790M muta-
tion, and four of the six tumors analyzed showed a secondary
somatic activating EGFR mutation (either L858R, del L747-
T751, or G719A) occurring in cis with the germ line T790M
mutation20; however, the T790M mutation was never found
among 237 lung cancer family probands.21 These results
suggest that the T790M mutation not only confers resistance
to EGFR-TKIs, but also grants growth advantage to cancer
cells (Figure 1C).
Although it was initially reported that the kinase activ-
ity of the EGFR T790M mutant was indistinguishable from
wild-type EGFR,5,6,14 Mulloy et al. showed that the T790M
mutant exhibits tyrosine phosphorylation levels comparable
to wild-type EGFR, whereas the T790M/L858R double mu-
tant exhibits a substantial increase in phosphorylation, com-
pared with the L858R mutant alone. Thus, the T790M resis-
tance mutation, when combined with activating EGFR kinase
domain mutations, confers a significant enhancement of its
catalytic phosphorylating activity, which suggests that these
mutations cooperate to produce a more potent kinase. This
may potentially explain the additional role of the T790M
mutation in predisposing to tumorigenesis.22 Vikis et al.21
further indicated that the T790M mutation alone leads to
increased phosphorylation levels. A human bronchial epi-
thelial cell line overexpressing EGFR carrying the T790M
mutation displayed a growth advantage over wild-type
EGFR.21
Animal models were generated to inducibly express the
T790M mutation, alone or together with the L858R mutation,
in type II pneumocytes that develop lung adenocarcinomas.
Mice expressing the T790M mutation alone develop tumors
with longer latency than those expressing both the T790M
and L858R mutations.23 In contrast to what is observed in
tumors of patients carrying human germ line T790M muta-
tions (discussed above), no additional kinase domain muta-
tions were detected in the tumors of these mice.23 These
results indicate that the T790M mutation is not only a cause
of resistance to gefitinib/erlotinib but is also an oncogenic
mutation that confers growth advantage to cancer cells. Its
oncogenic potential is maximized when the mutation arises in
combination with other common EGFR activating mutations
(Figure 1C).
Strategies to Overcome the Resistance
Conferred by the T790M Mutation
Since the T790M mutation confers resistance to ge-
fitinib/erlotinib by increasing the affinity of EGFR to ATP,
relative to that of EGFR to TKIs,18 it is possible to overcome
the resistance caused by this mechanism by developing a
novel class of EGFR-TKIs that have a higher affinity for the
T790M kinase, when compared with the affinity of ATP for
the mutant kinase. Several kinds of so-called second gener-
ation TKIs are currently in various stages of development.
BIBW2992,24 PF00299804,25 and HKI-27226 are examples of
this new type of EGFR-TKI and belong to the class of irrevers-
ible TKIs that covalently bind the sulfhydryl group of cysteine
797 at the catalytic pocket of EGFR (Figure 1D); however, Yun
et al.18 indicate that irreversible binding is not required for
effective inhibition of the T790M mutant: a reversible inhib-
itor that binds EGFR-T790M with an affinity sufficient to
compete with ATP should be as effective. Accordingly, the
XL647 is reported to inhibit the T790M EGFR mutant, even
though this compound is a reversible TKI.27 Nevertheless, it
should be noted that one of the acquired resistance mecha-
nisms was also the T790M mutation in the cell culture model
of acquired resistance to an irreversible EGFR-TKI, HKI-
272.28 This observation seems to be somewhat puzzling, but
it reflects the fact that HKI-272 can overcome T790M only at
high doses (approximately 1 M), but not at clinically
achievable concentrations (approximately 0.2 M).28
Inhibition of the heat shock protein 90 (HSP90) is also
effective in inhibiting the T790M mutant.29 Addition of
rapamycin (an inhibitor of mammalian target of rapamycin
[mTOR]) to irreversible TKI potentiates the antitumor effect
in the L858R/T790M mouse model.26
MET Amplification and Other Mechanisms for
Acquired Resistance to TKI Treatment
Over 50 secondary mutations of the ABL gene are
reported in acquired resistance to imatinib in chronic myeloid
leukemia30; however, the EGFR D761Y and L747S muta-
tions are the only two other rare examples of secondary
mutations associated with acquired resistance to gefitinib
(other than T790M).15,31
In 2007, Engelman et al.32 reported amplification of
MET, a receptor tyrosine kinase for hepatocyte growth factor,
as another mechanism of resistance to EGFR-TKIs. The
authors isolated gefitinib-resistant clones from HCC827 lung
cancer cells (EGFR exon 19 deletion and amplified) by
exposing the cells to increasing concentration of gefitinib.
The resistant cells maintained activation of the ERBB3/
PI3K/Akt antiapoptotic pathway in the presence of gefitinib.
The resistant cells but not parental cells harbor MET ampli-
fication by a factor of 5 to 10, and inhibition of MET by
specific TKI restores gefitinib sensitivity. They concluded
that MET amplification activates the PI3K/Akt pathway
through ERBB3 activation.32 MET amplification is present in
about 20% of patients with acquired resistance but only in 3%
of untreated patients.32,33 Interestingly, MET amplification
sometimes coexists with the T790M mutation,32,33 and one
patient is reported to have two independent resistant tumors;
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one of which had the T790M mutation, whereas the other had
MET amplification.32 More recently, it was shown that hy-
perphosphorylation of the insulin-like growth factor I (IGF-I)
receptor (IGF-IR) and constitutive association of IRS-1 with
PI3K through loss of expression of IGF binding protein in
gefitinib-treated cells is another mechanism of acquired re-
sistance.34
The mechanisms underlying acquired resistance to ge-
fitinib/erlotinib treatment are still unknown in more than 30%
of cases. Further clarification of the pathways leading to
acquired resistance is essential to maximize the efficacy of
EGFR-TKI therapy in patients with non-small cell lung
cancer.
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